New drug cocktail targets Hard-to-Treat stomach cancer
NCT ID NCT06947291
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of two drugs—glumetinib (a targeted therapy) and a special form of docetaxel (chemotherapy)—in people with advanced stomach cancer or other solid tumors that have a specific genetic marker called MET overexpression. The trial has two stages: first to find the best dose, then to see if the combo shrinks tumors. About 350 adults are being recruited across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glumetinib tablets and docetaxel (albumin-bound) injection
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced gastric cancer that has MET overexpression, potentially shrinking tumors and delaying progression.
- What could go wrong
- This is an early-phase trial (Phase 2) with a small number of participants, so results may not apply to everyone. The combination may cause side effects like fatigue, low blood counts, or allergic reactions, and it may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?